Prelude Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
PRLD$3.76+4.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Changes in Stockholders’ Equity (Unaudited)
STATEMENTS OF CHANGES INSTOCKHOLDERS’ EQUITY
| Voting common stock · Non-voting commonstock · Additional paid-in · Accumulated other comprehensive · Accumulated | ||||||||
|---|---|---|---|---|---|---|---|---|
| (in thousands, except shares) | Shares | Amount | Shares | Amount | capital | loss | deficit | Total |
| Balance at January 1, 2024 | 42,063,995 | $4 | 12,850,259 | $1 | $693,252 | $223 | $(456,390) | $237,090 |
| Issuance of common stock upon exercise of stock options & vesting of RSUs, net of 4,285 shares withheld for employee taxes | 7,510 | — | — | — | (14) | — | — | (14) |
| Unrealized loss on marketable securities, net of tax | — | — | — | — | — | (458) | — | (458) |
| Stock-based compensation expense | — | — | — | — | 5,547 | — | — | 5,547 |
| Net loss | — | — | — | — | — | — | (31,431) | (31,431) |
| Balance at March 31, 2024 | 42,071,505 | $4 | 12,850,259 | $1 | $698,785 | $(235) | $(487,821) | $210,734 |
| Voting common stock · Non-voting common stock · Additional paid-in · Accumulated other comprehensive · Accumulated | ||||||||
|---|---|---|---|---|---|---|---|---|
| (in thousands, except shares) | Shares | Amount | Shares | Amount | capital | loss | deficit | Total |
| Balance at January 1, 2023 | 36,496,994 | $4 | 11,402,037 | $1 | $531,682 | $(1,692) | $(334,558) | $195,437 |
| Issuance of common stock upon exercise of stock options & vesting of RSUs | 17,224 | — | — | — | 28 | — | — | 28 |
| Unrealized gain on marketable securities, net of tax | — | — | — | — | — | 1,294 | — | 1,294 |
| Stock-based compensation expense | — | — | — | — | 6,256 | — | — | 6,256 |
| Net loss | — | — | — | — | — | — | (27,718) | (27,718) |
| Balance at March 31, 2023 | 36,514,218 | $4 | 11,402,037 | $1 | $537,966 | $(398) | $(362,276) | $175,297 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.